ALT Stock Overview
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$5.16|
|52 Week High||US$19.46|
|52 Week Low||US$3.83|
|1 Month Change||-1.34%|
|3 Month Change||-31.11%|
|1 Year Change||-61.43%|
|3 Year Change||110.61%|
|5 Year Change||-96.12%|
|Change since IPO||-97.83%|
Recent News & Updates
Altimmune's New Avatar As A Liver Disease Player
Altimmune used to be an infectious disease player. After a lot of upheavals last year, it has now moved on to obesity, NASH and NAFLD. I am curious to see how this evolves.
|ALT||US Biotechs||US Market|
Return vs Industry: ALT underperformed the US Biotechs industry which returned -21.7% over the past year.
Return vs Market: ALT underperformed the US Market which returned -10.4% over the past year.
|ALT Average Weekly Movement||11.5%|
|Biotechs Industry Average Movement||12.3%|
|Market Average Movement||7.8%|
|10% most volatile stocks in US Market||16.7%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: ALT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: ALT's weekly volatility (12%) has been stable over the past year.
About the Company
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company’s lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus.
Altimmune Fundamentals Summary
|ALT fundamental statistics|
Is ALT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ALT income statement (TTM)|
|Cost of Revenue||US$79.73m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-2.37|
|Net Profit Margin||-2,820.39%|
How did ALT perform over the long term?See historical performance and comparison
Is Altimmune undervalued compared to its fair value and its price relative to the market?
Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ALT's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ALT's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: ALT is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: ALT is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ALT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ALT is good value based on its PB Ratio (1.2x) compared to the US Biotechs industry average (1.4x).
How is Altimmune forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ALT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ALT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ALT's revenue (92.7% per year) is forecast to grow faster than the US market (8% per year).
High Growth Revenue: ALT's revenue (92.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ALT's Return on Equity is forecast to be high in 3 years time
How has Altimmune performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALT is currently unprofitable.
Growing Profit Margin: ALT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ALT is unprofitable, and losses have increased over the past 5 years at a rate of 22.1% per year.
Accelerating Growth: Unable to compare ALT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: ALT has a negative Return on Equity (-54.99%), as it is currently unprofitable.
How is Altimmune's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: ALT's short term assets ($191.1M) exceed its short term liabilities ($19.1M).
Long Term Liabilities: ALT's short term assets ($191.1M) exceed its long term liabilities ($1.7M).
Debt to Equity History and Analysis
Debt Level: ALT is debt free.
Reducing Debt: ALT has no debt compared to 5 years ago when its debt to equity ratio was 14.5%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ALT has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ALT has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 45% each year.
What is Altimmune current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ALT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALT's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ALT has not reported any payouts.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Vipin Garg (63 yo)
Dr. Vipin K. Garg, Ph D., has been the President, Chief Executive Officer and Director of Altimmune, Inc. since November 30, 2018. Dr. Garg joined Altimmune in November 2018 with over three decades of expe...
CEO Compensation Analysis
Compensation vs Market: Vipin's total compensation ($USD2.63M) is above average for companies of similar size in the US market ($USD1.69M).
Compensation vs Earnings: Vipin's compensation has increased whilst the company is unprofitable.
Experienced Management: ALT's management team is considered experienced (3.7 years average tenure).
Experienced Board: ALT's board of directors are considered experienced (5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16%.
Altimmune, Inc.'s employee growth, exchange listings and data sources
- Name: Altimmune, Inc.
- Ticker: ALT
- Exchange: NasdaqGM
- Founded: 1997
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$221.433m
- Shares outstanding: 42.91m
- Website: https://altimmune.com
Number of Employees
- Altimmune, Inc.
- 910 Clopper Road
- Suite 201S
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/15 00:00|
|End of Day Share Price||2022/05/13 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.